Evidence map›Paper›PMID 39186243›Full record

ReviewJournal of hematopathology2024

Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy.

Alireza Torabi, Jason Love, Teresa Hyun, Angie Pham, Jordan Gauthier, Alexandre Hirayama, David Wu, Kikkeri Naresh

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Journal of hematopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alireza TorabiDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle 1959 NE Pacific Street, Box 357110, Seattle, WA, 98195, USA. alirezat@uw.edu.ORCID http://orcid.org/0000-0001-8272-0279
Jason LoveDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle 1959 NE Pacific Street, Box 357110, Seattle, WA, 98195, USA.
Teresa HyunDepartment of Hematopathology, Fred Hutch Cancer Center, Seattle, WA, USA.
Angie PhamCellnetix Pathology Group, Seattle, WA, USA.
Jordan GauthierClinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA.
Alexandre HirayamaClinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA.
David WuDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle 1959 NE Pacific Street, Box 357110, Seattle, WA, 98195, USA.
Kikkeri NareshDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle 1959 NE Pacific Street, Box 357110, Seattle, WA, 98195, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted immunotherapy is a promising approach in treating high-risk and refractory/relapsed lymphoid malignancies. Although this strategy has shown a significant success in treating non-Hodgkin B-cell lymphomas and plasma cell myeloma, relapse with loss of targeted antigen can occur. Rarely, complete loss of multiple lineage specific markers can happen. We are describing 2 cases of B-cell neoplasms along with contributing immunohistochemistry, cytogenetic, and molecular results. Post-targeted CAR-T therapy, both cases, one aggressive B-cell lymphoma and the other plasma cell myeloma, lost B-cell, and plasma cell antigens, respectively. Complete loss of lineage specific markers post-targeted therapy is a rare event that makes the diagnosis of the relapsed neoplasm challenging. In this article, we also reviewed the literature and highlighted possible mechanisms of antigen loss following targeted therapy.

Indexed as

Immunotherapy, AdoptiveLymphoma, B-CellAntigens, NeoplasmBiomarkers, TumorFemaleHumansMaleMiddle AgedMultiple MyelomaReceptors, Chimeric AntigenAntigens, NeoplasmBiomarkers, TumorReceptors, Chimeric AntigenB-cell lymphomaCAR-T therapyPlasma cell neoplasmRefractory/relapsed

Identifiers

PMID39186243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.